Drugs / YD02-2022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05990530 | Feb 2023 → Aug 2024 | type 1 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YD02-2022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05990530 ↗ |
| Modality | Cell therapy | “allogeneic pancreatic islet cells transplantation” NCT05990530 ↗ |
| Route | Other | “infused into the hepatic portal vein.” NCT05990530 ↗ |